Amgen, Novartis and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program. An assessment of data during a pre-planned review identified worsening in some measures of cognitive function. The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. The Generation Program was designed to re...